Last reviewed · How we verify

Disorder due to type 2 diabetes mellitus — Treatment Landscape & Competitive Intelligence

Disorder due to type 2 diabetes mellitus (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disorder due to type 2 diabetes mellitus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Micardis TELMISARTAN Boehringer Ingelheim Angiotensin 2 Receptor Blocker [EPC] Type-2 angiotensin II receptor 1998-01-01
Pritor Pritor DongKoo Bio & Pharma ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Boehringer Ingelheim · 1 drug in Disorder due to type 2 diabetes mellitus
  2. DongKoo Bio & Pharma · 1 drug in Disorder due to type 2 diabetes mellitus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disorder due to type 2 diabetes mellitus:

Cite this brief

Drug Landscape (2026). Disorder due to type 2 diabetes mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-due-to-type-2-diabetes-mellitus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing